Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilostazol/probucol - Otsuka Pharmaceutical

Next Previous
X
Search
Drug Profile

Cilostazol/probucol - Otsuka Pharmaceutical

Alternative Names: cilostazol 100mg/probucol 250mg; LPC-01; P250/C100; probucol/cilostazol

Latest Information Update: 15 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihyperlipidaemics; Antiplatelets; Phenols; Small molecules; Tetrazoles
  • Mechanism of Action Antioxidants; Free radical scavengers; Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 15 Feb 2022 Discontinued - Phase-I for Atherosclerosis (In volunteers) in Japan (PO) before February 2022 (Otsuka Pharmaceutical pipeline, February 2022)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in Japan (PO, Tablet)
  • 03 Jun 2016 Chemical information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top